Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 529–552 of 3,752 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Phase duration Clear all
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Behavioral Rx & Nutrition in Pediatric Chronic Disease

NCT01018121
View directory record Official record
Conditions
Pediatric Obesity
Interventions
LAUNCH, Pediatrician Counseling
Behavioral · Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
2 Years to 5 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2009 · Synced Oct 28, 2026, 5:06 AM EDT
Recruiting Not applicable Interventional

The LYMPH Trial - Microsurgical Versus Conservative Treatment of Chronic Breast Cancer Associated Lymphedema

NCT05890677
View directory record Official record
Conditions
Lymphedema, Breast Cancer
Interventions
Surgical Intervention, Conservative Complex Physical Decongestion Therapy
Procedure
Lead sponsor
University Hospital, Basel, Switzerland
Other
Eligibility
18 Years and older
Enrollment
280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2036
U.S. locations
4
States / cities
New Haven, Connecticut • Boston, Massachusetts • Rochester, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 4 Interventional Results available

POWER (Pulse Width Optimized Waveform Evaluation Trial)

NCT00311181
View directory record Official record
Conditions
Sudden Cardiac Death
Interventions
Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
2
States / cities
Birmingham, Alabama • Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Not applicable Interventional

Mindfulness-Based Blood Pressure Reduction: Stage 2a RCT

NCT03256890
View directory record Official record
Conditions
Hypertension, Prehypertension
Interventions
MB-BP Intervention, Enhanced Usual Care Control
Behavioral · Other
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Oct 28, 2026, 5:06 AM EDT
Terminated Phase 1 Interventional Results available

A First Time in Human (FTIH) Study of GSK3745417 Administered to Participants With Advanced Solid Tumors

NCT03843359
View directory record Official record
Conditions
Neoplasms
Interventions
GSK3745417, Dostarlimab
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 3, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Trial of Surgery and Fractionated Re-Irradiation for Recurrent Ependymoma

NCT02125786
View directory record Official record
Conditions
Ependymoma
Interventions
Irradiation, Surgery, ^1^8F-Fluorodeoxyglucose, ^1^1C-methionine, Photon therapy, Proton therapy
Radiation · Procedure · Drug + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 21 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Active, not recruiting Phase 3 Interventional

HERTHENA-Lung02: A Study of Patritumab Deruxtecan Versus Platinum-based Chemotherapy in Metastatic or Locally Advanced EGFRm NSCLC After Failure of EGFR TKI Therapy

NCT05338970
View directory record Official record
Conditions
Nonsquamous Non-small Cell Lung Cancer, EGFR L858R, EGFR Exon 19 Deletion
Interventions
Patritumab Deruxtecan, Platinum-based chemotherapy
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
586 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Anchorage, Alaska • Springdale, Arkansas • Duarte, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Effectiveness of Lyophilized Certolizumab Pegol in the Treatment of Signs and Symptoms of Rheumatoid Arthritis and in Prevention of Joint Damage in Patients With Active Rheumatoid Arthritis

NCT00175877
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Certolizumab Pegol
Biological
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years and older
Enrollment
857 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
19
States / cities
Huntsville, Alabama • San Diego, California • Danbury, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2020 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

Antidepressant Treatment Plus Cognitive Behavioral Therapy for Generalized Anxiety Disorder in Older Adults

NCT00601965
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Escitalopram, Placebo, Cognitive behavioral therapy (CBT)
Drug · Behavioral
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
60 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
3
States / cities
San Diego, California • St Louis, Missouri • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 25, 2016 · Synced Oct 28, 2026, 5:06 AM EDT
Recruiting Phase 2Phase 3 Interventional

Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract Cancer

NCT04628767
View directory record Official record
Conditions
Renal Pelvis and Ureter Urothelial Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Cisplatin, Computed Tomography, Doxorubicin Hydrochloride, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Methotrexate, Pegfilgrastim, Therapeutic Conventional Surgery, Vinblastine Sulfate
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
258
States / cities
Kingman, Arizona • Fort Smith, Arkansas • Little Rock, Arkansas + 197 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Not applicable Interventional

The Inflammatory Bowel Disease - Anti-Inflammatory Diet (IBD-AID)

NCT04757181
View directory record Official record
Conditions
Inflammatory Bowel Diseases
Interventions
The IBD-AID
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
15 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Assess Efficacy of RXC004 +/- Nivolumab in Ring Finger Protein 43 (RNF43) or R-spondin (RSPO) Aberrated, Metastatic, Microsatellite Stable, Colorectal Cancer After Progression on Standard of Care (SOC)

NCT04907539
View directory record Official record
Conditions
Colorectal Cancer
Interventions
RXC004, Nivolumab, Denosumab
Drug · Biological
Lead sponsor
Redx Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Santa Rosa, California • Indianapolis, Indiana • Las Vegas, Nevada + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2025 · Synced Oct 28, 2026, 5:06 AM EDT
Recruiting Phase 1 Interventional

IS-free Treg HaploHCT

NCT04678401
View directory record Official record
Conditions
Stem Cell Transplant Complications, Graft Vs Host Disease, Myeloid Leukemia, Acute, Myeloid Leukemia in Relapse (Disorder), Myelodysplastic Syndromes
Interventions
Radiation, Fludarabine, Thiotepa, Cyclophosphamide, Mesna, Treg-enriched donor cell, Unmodified donor T Cell, CD34+ Haplo Peripheral Blood Stem Cell, Melphalan
Radiation · Drug · Biological + 1 more
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 28, 2026, 5:06 AM EDT
Active, not recruiting Phase 2 Interventional

Study of Iberdomide in People With Multiple Myeloma Who Have Had an Autologous Hematopoietic Stem Cell Transplant (AHCT)

NCT05354557
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Iberdomide
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
8
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Adjuvant Quisinostat in High-Risk Uveal Melanoma

NCT06932757
View directory record Official record
Conditions
Uveal Melanoma
Interventions
Quisinostat
Drug
Lead sponsor
University of Miami
Other
Eligibility
19 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 18, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Lymphocyte Re-infusion During Immune Suppression to Treat Metastatic Melanoma

NCT00001832
View directory record Official record
Conditions
Melanoma, Neoplasm Metastasis
Interventions
gp100:209-217 (210M), Montanide ISA-51, IL-2, MART-1:26-35(27L), Abl cells, Fludarabine, Cyclophosphamide, GCSF (Growth colony stimulating factor), Apheresis
Drug · Biological · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
7 Years and older
Enrollment
170 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 21, 2012 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Not applicable Interventional Results available

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

NCT00569309
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
Interventions
Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
Biological · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 28, 2026, 5:06 AM EDT
Active, not recruiting Phase 1 Interventional

Study of Venetoclax in Combination With Decitabine in Subjects With Acute Myeloid Leukemia

NCT03844815
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Decitabine, Venetoclax
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 3 Interventional

Phase 3, Open-label Clinical Trial of EB-101 for the Treatment of Recessive Dystrophic Epidermolysis Bullosa (RDEB)

NCT04227106
View directory record Official record
Conditions
Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions
EB-101
Biological
Lead sponsor
Abeona Therapeutics, Inc
Industry
Eligibility
6 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
2
States / cities
Redwood City, California • Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 5, 2022 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Oral Levonorgestrel Plus Meloxicam, IG-002 Delays Ovulation in Normal Menstruating Women by Seven Days

NCT05695352
View directory record Official record
Conditions
Pregnancy Prevention
Interventions
Levonorgestrel 1.5mg, Meloxicam 15 mg, Placebo
Drug · Other
Lead sponsor
InnovaGyn, Inc.
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Raleigh, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Feasibility of Home-based tES for Older Adults at Risk of Falling

NCT04732533
View directory record Official record
Conditions
Aging, Accidental Falls
Interventions
tES (transcranial electrical stimulation)
Other
Lead sponsor
Hebrew SeniorLife
Other
Eligibility
60 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Roslindale, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Phase 3 Interventional

Individual PE vs Couples' CBT for Combat-Related Posttraumatic Stress Disorder

NCT02336971
View directory record Official record
Conditions
PTSD, Marital Relationship
Interventions
CBCT for PTSD, Prolonged Exposure
Behavioral
Lead sponsor
Toronto Metropolitan University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
3
States / cities
Fort Hood, Texas • Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 28, 2026, 5:06 AM EDT
Withdrawn Phase 1 Interventional

A Study of Oral L-citrulline in Sickle Cell Disease

NCT02659644
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Oral L-citrulline
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
10 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Jun 21, 2018 · Synced Oct 28, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Active Approach to Treat Amblyopia: Video Game Play

NCT01223716
View directory record Official record
Conditions
Amblyopia
Interventions
Perceptual learning, Video Game, Crossover (Occlusion therapy + Video Game)
Behavioral
Lead sponsor
University of California, Berkeley
Other
Eligibility
5 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2009
U.S. locations
1
States / cities
Berkeley, California
Source: ClinicalTrials.gov public record
Updated May 17, 2016 · Synced Oct 28, 2026, 5:06 AM EDT